Anti s6 2217

Anti-PARP (#9542), anti-Bcl-xL (#2762), anti-Bcl-2(#2876), anti-GAPDH (#2118), anti-cyclin D1 (#2922), anti-phospho-Rb(S807/811) (#9308), anti-Rb (#9309), anti-cleaved caspase 3 (#9661), anti-phospho-p70 S6 kinase(Thr389) (#9205), anti-S6 (#2217) and anti-phospho-S6(Ser240/244) (#5364) antibodies were from Cell Signaling Technology. Anti-phospho-STAT3(Y705) (sc-8059), anti-STAT3 (sc-7179), anti-phospho-Erk(T204) and anti-Mcl-1(sc-819) antibodies were from Santa Cruz Biotechnology. Anti-Erk (#06-182) and anti-gp130 (#06-291) antibodies were from Upstate. Anti-α-tubulin (T5168) antibody, water-soluble cholesterol (C4591) and Tyron were from Sigma Aldrich. Anti-Ki67 (#RM-9106-R7) antibody was from Thermo Scientific. Horseradish peroxidase-labeled secondary antibodies were from Jackson ImmunoResearch Laboratories. Secondary HRP-Polymer MACH3 (#M3RS31) antibody was from BioCare Medical. Secondary ImmPRESS (#MP-7401) antibody was from Vector Laboratories. Amplex Red Cholesterol assay kit (A12216) was from Molecular Probes. Recombinant IL-6 was from Pepro Tech. EUK207 was from Shirichai Orian, UCLA. MEDICA analog [HOOC-C(CH₃)₂-(CH₂)₁₂-C(CH₃)₂-COOH] was synthesized as previously described^{11 (link)}. Bortezomib was from Janssen Pharmaceutica.

The following antibodies and reagents were used for the Western blotting experiments. Anti-LC3 (5F10, Nanotools), anti-S6 (2217, Cell Signaling Technology, Danvers, MA, USA), anti-phospho-S6 (4858, Cell Signaling Technology), anti-cleaved caspase 3 (9664, Cell Signaling Technology), anti-SQSTM1/p62 (P0067, Sigma-Aldrich, Saint-Louis, MO, USA), anti-Bcl-2 (sc-492, Santa Cruz Biotechnology, Dallas, TX, USA), and anti-Bax (sc-493, Santa Cruz Biotechnology). Anti-GAPDH (G8715, Sigma-Aldrich) served as an internal control. Secondary antibodies are HRP-linked anti-mouse IgG (7076, Cell Signaling Technology) and HRP-linked anti-rabbit IgG (1706515, Bio-Rad Laboratories, Hercules, CA, USA).